“sr-one” Archives

in
Entry Author Date Location
Bio Roundup: Blackstone’s Billions, Biogen Finishes Filing, Novavax at “Warp Speed” & More 07/10/20 National
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic 05/21/20 Boston
Pandion Pulls In $80M as Ulcerative Colitis Drug Advances in Clinic 04/01/20 Boston
Ideaya and Bicycle Therapeutics IPOs Raise $110M for Cancer Drug R&D 05/23/19 San Francisco
Turning Point Therapeutics Plans IPO to Advance Targeted Cancer Drugs 03/22/19 San Diego
ResMed Boosts Connected Health Play With $225M Propeller Health Deal 12/03/18 Wisconsin
TP Therapeutics Names New CEO, Gets $80M More for Cancer Drug Push 10/19/18 San Diego
Entasis Therapeutics and Principia Biopharma Join the IPO Queue 08/20/18 Boston
Decibel Hauls in $55M to Bring Multiple Hearing Drugs to the Clinic 06/19/18 Boston
Nimbus Nabs $65M to Advance In-House Drug Discoveries to the Clinic 06/05/18 Boston
Propeller Health Raises $20M to Move Beyond Respiratory Disease 05/30/18 Wisconsin
Macrolide Pharma Raises $20M, Names Former Intarcia Exec Karande CEO 04/02/18 Boston
Pandion Raises $58M to Bring Cancer-Fighting Tactics to Immune Disorders 01/18/18 Boston
Spero, Allena Nab $152M As Bio IPOs, With Insider Help, Continue Roll 11/02/17 Boston
Palleon Lands $48M to Develop New Type of Checkpoint Cancer Drug 10/04/17 Boston
Effector Raises $38.6M to Advance New Class of Anti-Cancer Drugs 07/25/17 San Diego
Not Resting on Hemophilia Biz, Bioverativ Pays $400M For True North 05/23/17 Boston
With $145M Buyout, River Vision’s Plan For Stalled Roche Drug Pays Off 05/08/17 New York
ZappRx Gets $25M to Push E-Prescription Tools for Specialty Meds 04/20/17 Boston
Frequency, Led by MIT’s Langer, Aims to Fight Hearing Loss With Drugs 01/05/17 Boston
RaNA Expands, Joins Messenger RNA Drug Race With Shire Deal 01/04/17 Boston
Propeller Health Receives $21,500,000 Series C Round 10/21/16 Wisconsin
Propeller Health Raises $21.5M for Respiratory Disease Technology 10/20/16 Wisconsin
With New Name and $86M, Tioma To Explore Anti-CD47 Cancer Therapy 08/16/16 San Francisco
Second Genome Replaces DiLaura as CEO, Brings Series B to $51M 07/13/16 San Francisco
Morphic Therapeutic Garners $51,500,000 Series A Funding 06/30/16 Boston
Five Takeaways from “What’s Hot in Boston Biotech” 04/11/16 Boston
Startups Begin to Emerge From NYU’s “Virtual” Biotech Factory 03/17/16 New York
Viehbacher, Sharp & More at What’s Hot in Boston Biotech on April 6 02/18/16 Boston
Spero Eyes First Trial, Gets $30M More to Battle Drug-Resistant Bugs 02/02/16 Boston
Page 1 of 6 next page »